MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
BioCryst Pharmaceuticals Interest Expense 2011-2026 | BCRX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense BioCryst Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 108 M | 99.1 M | 59.3 M | 14.5 M | 11.9 M | 9.18 M | 8.56 M | 6.49 M | 5.2 M | 5 M | 4.78 M | 4.67 M | 3.77 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 108 M | 3.77 M | 26.2 M |
Quarterly Interest Expense BioCryst Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.46 M | - | - | - | - | - | 24.7 M | 24.5 M | - | 27.3 M | 28.9 M | 27.4 M | - | 24.8 M | 24 M | 23.8 M | - | 14.1 M | 13.5 M | 12.9 M | - | 2.93 M | 2.92 M | 3.05 M | - | 3.04 M | 3.04 M | 2.73 M | - | 2.35 M | 2.2 M | 2.22 M | - | 2.14 M | 2.09 M | 2.1 M | - | 1.46 M | 1.42 M | 1.47 M | - | 1.24 M | 1.31 M | 1.32 M | - | 1.22 M | 1.22 M | 1.24 M | - | 1.19 M | 1.16 M | 1.18 M | - | 1.17 M | 1.16 M | 1.16 M | - | 1.16 M | 1.17 M | 288 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.9 M | -1.46 M | 7.07 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
9.34 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M |  Germany |
 |
Coherus BioSciences
CHRS
|
9 M | $ 1.57 | -3.68 % | $ 184 M |  USA |
 |
Happiness Biotech Group Limited
HAPP
|
262 K | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 16.87 | -2.49 % | $ 789 M | USA |
 |
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
722 K | - | - | $ 866 M | China |
 |
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B |  France |
 |
Arcturus Therapeutics Holdings
ARCT
|
10.1 M | $ 7.47 | -4.6 % | $ 205 M |  Israel |
 |
Athira Pharma
ATHA
|
1.24 M | - | - | $ 269 M | USA |
 |
Eton Pharmaceuticals
ETON
|
1.06 M | $ 30.26 | 1.0 % | $ 814 M | USA |
 |
Galera Therapeutics
GRTX
|
11.4 M | - | -32.59 % | $ 7.61 M | USA |
 |
Exelixis
EXEL
|
-198 K | $ 50.13 | -1.9 % | $ 13.6 B | USA |
 |
Fortress Biotech
FBIO
|
17.6 M | $ 2.41 | 4.78 % | $ 67.2 M | USA |
|
Forte Biosciences
FBRX
|
-396 K | $ 23.11 | -3.55 % | $ 299 M | USA |
 |
AbCellera Biologics
ABCL
|
-2.71 M | $ 4.09 | -7.05 % | $ 1.22 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.63 | 2.52 % | $ 434 M |  Britain |
 |
BioNTech SE
BNTX
|
14.2 M | $ 89.55 | -2.65 % | $ 21.6 B | Germany |
 |
Galectin Therapeutics
GALT
|
1.03 M | $ 2.17 | -7.66 % | $ 139 M | USA |
 |
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | USA |
 |
IMV
IMV
|
2.34 K | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | USA |
 |
Gilead Sciences
GILD
|
-1 M | $ 129.58 | -1.88 % | $ 161 B | USA |
 |
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 3.36 | -3.72 % | $ 5.53 M | Israel |
 |
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
1.93 M | $ 0.72 | -1.58 % | $ 32.9 M | Israel |
 |
Esperion Therapeutics
ESPR
|
3.49 M | $ 3.12 | - | $ 649 M | USA |
 |
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-43 K | - | - | $ 28.6 M | USA |